Serum Interleukin-6 in Schizophrenia: Associations with Clinical and Sociodemographic Characteristics

Abstract

BACKGROUND: Recently a significant part of schizophrenia studies have been focused on the role of cytokines, especially interleukin-6 (IL-6). Some authors have suggested a pathogenetic role for IL-6 in schizophrenia and concluded that therapy that centers on suppressing IL-6 activity may prove beneficial for certain categories of patients with the disorder. However, many questions about whether the changes in IL-6 levels in schizophrenia are primary, related to symptoms or caused by therapy, are concomitant metabolic disorders, are related to smoking or other secondary factors remain unanswered.

AIM: To assess the level of serum IL-6 in patients with schizophrenia in comparison with healthy controls, as well as to study its association with clinical and socio-demographic characteristics.

METHODS: Some 125 patients with schizophrenia and 95 healthy volunteers were examined. The evaluation of IL-6 was performed by enzyme immunoassay. All patients were assessed using standardized psychometric instruments. Information from patient medical records on the course of the disease and treatment was analyzed.

RESULTS: The level of IL-6 was significantly higher in the patients than in the healthy volunteers (z=2.58; p=0.0099), but among men the difference between the patients and volunteers was not significant. Statistically significant correlations were found between the level of serum IL-6 and the severity of the cognitive impairment of patients: (auditory [ρ=–0.31; p=0.00063] and working memory [ρ=−0.25; p=0.0065], hand-eye coordination [ρ=−0.29; p=0.0011], verbal fluency [ρ=−0.28; p=0.0019] and problem-solving capacity [ρ=−0.22; p=0.013]), total severity of schizophrenia symptoms (PANSS, ρ=0.22; p=0.016), PANSS positive subscale (ρ=0.18; p=0.048), and the age of manifestation (ρ=0.20; p=0.025) and disease duration (ρ=0.18; p=0.043). The level of IL-6 was the lowest in patients treated with third-generation antipsychotics, and the highest in those treated with first-generation antipsychotics (H=6.36; p=0.042). Moreover, in hospital patients, the level of IL-6 was significantly higher than in outpatients and inpatients hospitals (H=18.59; p=0.0001).

CONCLUSION: The study confirmed that there are associations between the serum IL-6 level and schizophrenia, the age of the patient, duration of the disease and how late in one's life cycle it began manifesting itself, as well as a number of clinical characteristics. Considering that IL-6 is associated with a wide range of symptoms that are loosely controlled by antipsychotics, this biochemical marker needs to be studied to look into how closely its level tracks with an unfavorable course of schizophrenia. That would require further prospective studies.

Keywords

interleukin-6 / schizophrenia / cognitive symptoms

References

[1] Tandon R, Gaebel W, Barch DM et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150(1):3–10. doi: 10.1016/j.schres.2013.05.028.

[2] Miller BJ, Buckley P, Seabolt W et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663–71. doi: 10.1016/j.biopsych.2011.04.013.

[3] Potvin S, Stip E, Sepehry AA et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008;63(8):801–8. doi: 10.1016/j.biopsych.2007.09.024.

[4] Na KS, Jung HY, Kim YK. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:277–86. doi: 10.1016/j.pnpbp.2012.10.022.

[5] Borovcanin MM, Jovanovic I, Radosavljevic G et al. Interleukin-6 in Schizophrenia-Is There a Therapeutic Relevance? Front Psychiatry. 2017;8:221. doi: 10.3389/fpsyt.2017.00221.

[6] Fang X, Wang Y, Chen Y et al. Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics. Neuropsychiatr Dis Treat. 2019;15:2161-2170. doi: 10.2147/NDT.S202159.

[7] Zhou X, Tian B, Han HB. Serum interleukin-6 in schizophrenia: A system review and meta-analysis. Cytokine. 2021;141:155441. doi: 10.1016/j.cyto.2021.155441.

[8] Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. 2016;1863(6 Pt A):1218–27. doi: 10.1016/j.bbamcr.2016.03.018.

[9] García-Juárez M, Camacho-Morales A. Defining the Role of Anti- and Pro-inflammatory Outcomes of Interleukin-6 in Mental Health. Neuroscience. 2022;492:32–46. doi: 10.1016/j.neuroscience.2022.03.020.

[10] Khandaker GM, Pearson RM, Zammit S et al. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry. 2014;71(10):1121–8. doi: 10.1001/jamapsychiatry.2014.1332.

[11] Borovcanin M, Jovanovic I, Radosavljevic G et al. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatr Res. 2012;46(11):1421–6. doi: 10.1016/j.jpsychires.2012.08.016.

[12] Stojanovic A, Martorell L, Montalvo I et al. Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology. 2014;41:23–32. doi: 10.1016/j.psyneuen.2013.12.005.

[13] Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–709. doi: 10.1038/mp.2016.3.

[14] Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res. 2014;155(1-3):101–8. doi: 10.1016/j.schres.2014.03.005.

[15] Capuzzi E, Bartoli F, Crocamo C et al. Acute variations of cytokine levels after antipsychotic treatment in drug-naïve subjects with a first-episode psychosis: A meta-analysis. Neurosci Biobehav Rev. 2017;77:122–8. doi: 10.1016/j.neubiorev.2017.03.003.

[16] Bian Q, Kato T, Monji A et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):42–8. doi: 10.1016/j.pnpbp.2007.06.031.

[17] Røge R, Møller BK, Andersen CR et al. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res. 2012;140(1-3):204–13. doi: 10.1016/j.schres.2012.06.020.

[18] Kluge M, Schuld A, Schacht A et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology. 2009;34(1):118–28. doi: 10.1016/j.psyneuen.2008.08.016.

[19] Löffler S, Löffler-Ensgraber M, Fehsel K, Klimke A. Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients. Int Clin Psychopharmacol. 2010;25(2):101–6. doi: 10.1097/YIC.0b013e32833643fd.

[20] Marcinowicz P, Więdłocha M, Zborowska N et al. A Meta-Analysis of the Influence of Antipsychotics on Cytokines Levels in First Episode Psychosis. J Clin Med. 2021;10(11):2488. doi: 10.3390/jcm10112488.

[21] Dennison U, McKernan D, Cryan J, Dinan T. Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype. Psychol Med. 2012;42(9):1865–71. doi: 10.1017/S0033291712000074.

[22] Aldaham S, Foote JA, Chow HH, Hakim IA. Smoking Status Effect on Inflammatory Markers in a Randomized Trial of Current and Former Heavy Smokers. Int J Inflam. 2015;2015:439396. doi: 10.1155/2015/439396.

[23] Jamil A, Rashid A, Naveed AK, Asim M. Effect of smoking on interleukin-6 and correlation between IL-6 and serum amyloid a-low density lipoprotein in smokers. J Postgrad Med Institute. 2017;31(4). Available from: https://jpmi.org.pk/index.php/jpmi/article/view/2098

[24] Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76. doi: 10.1093/schbul/13.2.261.

[25] Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;(22):39–44.

[26] Snaith RP, Hamilton M, Morley S et al. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167(1):99–103. doi: 10.1192/bjp.167.1.99.

[27] Bush G, Fink M, Petrides G et al. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand. 1996;93(2):129–36. doi: 10.1111/j.1600-0447.1996.tb09814.x.

[28] Keefe RS, Harvey PD, Goldberg TE et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res. 2008;102(1-3):108–15. doi: 10.1016/j.schres.2008.03.024.

[29] Morosini PL, Magliano L, Brambilla L et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–9.

[30] Lingjaerde O, Ahlfors UG, Bech P et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100. doi: 10.1111/j.1600-0447.1987.tb10566.x.

[31] Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11–9. doi: 10.1111/j.1600-0447.1970.tb02066.x.

[32] Lane RD, Glazer WM, Hansen TE et al. Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. J Nerv Ment Dis. 1985;173(6):353–7. doi: 10.1097/00005053-198506000-00005.

[33] Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–6. doi: 10.1192/bjp.154.5.672.

[34] Bernstein DP, Stein JA, Newcomb MD et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl. 2003;27(2):169–90. doi: 10.1016/s0145-2134(02)00541-0.

[35] Patlola SR, Donohoe G, McKernan DP. The relationship between inflammatory biomarkers and cognitive dysfunction in patients with schizophrenia: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2023;121:110668. doi: 10.1016/j.pnpbp.2022.110668

[36] Kim K, Jeon HJ, Myung W et al. Clinical Approaches to Late-Onset Psychosis. J Pers Med. 2022;12(3):381. doi: 10.3390/jpm12030381.

[37] Tampi RR, Young J, Hoq R et al. Psychotic disorders in late life: a narrative review. Ther Adv Psychopharmacol. 2019;9:2045125319882798. doi: 10.1177/2045125319882798.

[38] Al-Diwani A, Handel A, Townsend L et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry. 2019;6(3):235–246. doi: 10.1016/S2215-0366(19)30001-X.

[39] Luo Y, Li J, Jiang F et al. Autoimmune Encephalitis With Psychotic Manifestations and Cognitive Impairment Presenting as Schizophrenia: Case Report and Literature Review. Front Psychiatry. 2022;13:827138. doi: 10.3389/fpsyt.2022.827138.

[40] Zhilyaeva TV, Piatoikina AS, Rukavishnikov GV, Mazo GE. Interleukin-6 in schizophrenia is associated with negative symptoms, side effects of therapy and smoking: results of a pilot study. V.M. Bekhterev review of psychiatry and medical psychology. 2022;56(2):47–55. doi: 10.31363/2313-7053-2022-56-2-47-55. Russian

[41] Kapelski P, Skibinska M, Maciukiewicz M et al. Family-based association study of interleukin 6 (IL6) and its receptor (IL6R) functional polymorphisms in schizophrenia in the Polish population. J Neuroimmunol. 2015;285:62–7. doi: 10.1016/j.jneuroim.2014.09.019.

[42] Paul-Samojedny M, Owczarek A, Kowalczyk M et al. Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFα) gene polymorphisms with paranoid schizophrenia in a Polish population. J Neuropsychiatry Clin Neurosci. 2013;25(1):72–82. doi: 10.1176/appi.neuropsych.12020021.

[43] Zakharyan R, Petrek M, Arakelyan A et al. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens.2012;80(2):136-42. doi: 10.1111/j.1399-0039.2012.01886.x.

Funding

Russian Foundation for Basic ResearchРоссийский фонд фундаментальных исследований(20-015-00301_А)

RIGHTS & PERMISSIONS

Zhilyaeva T.V., Rukavishnikov G.V., Manakova E.A., Mazo G.E.